Opinion

Video

Looking Ahead to Upcoming Presentations at ASH 2023

Expert insights into the evolving treatment landscape for chronic lymphocytic leukemia (CLL), emphasizing upcoming clinical data to be presented at ASH 2023.

This is a video synopsis/summary of an Insights featuring: Nicole Lamanna, MD.

Dr. Nicole Lamanna highlights key data that will be presented at the American Society of Hematology (ASH) 2023 annual meeting about advances in chronic lymphocytic leukemia (CLL) treatment. Several abstracts will provide long-term follow up from phase 3 trials of Bruton tyrosine kinase (BTK) inhibitors, demonstrating their sustained efficacy and safety. Other studies of interest include oral-only combinations of BTK and B-cell lymphoma 2 (BCL2) inhibitors or triplets adding in CD20 monoclonal antibodies. These all oral regimens may match or improve efficacy over historical chemoimmunotherapy. An abstract on BTK inhibitors plus PD1 blockade in Richter’s transformation addresses an area of high unmet need. There will also be updated data on newer agents like BTK degraders for overcoming resistance and noncovalent BTK inhibitors.

Overall, Dr. Lamanna highlights that the wealth of data on practice-changing advances in CLL treatment will be valuable features of ASH 2023.

Video synopsis is AI-generated and reviewed by OncLive® editorial staff.

Related Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Farrukh Awan, MD
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Minoo Battiwalla, MD, MS
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the role of genomic profiling in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss the treatment goals in secondary acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss factors for picking intensive chemotherapy vs other regimens in acute myeloid leukemia.
James K. McCluskey, MD, and Harry P. Erba, MD, PhD, discuss dose intensity and sequencing of CPX-351 in secondary acute myeloid leukemia.